<DOC>
	<DOCNO>NCT00729469</DOCNO>
	<brief_summary>The purpose study determine safety efficacy ospemifene postmenopausal woman experience moderate severe vaginal dryness vaginal pain associate sexual activity .</brief_summary>
	<brief_title>Efficacy Safety Ospemifene Treatment Moderate Severe Vaginal Dryness Vaginal Pain Associated With Sexual Activity</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Naturally surgically menopausal Moderate severe symptom vaginal atrophy 5 % few superficial cell maturation index vaginal smear Vaginal pH great 5.0 Self report Most Bothersome Symptom vaginal dryness vaginal pain associate sexual activity , severity moderate severe randomization Uterine bleed unknown origin , uterine polyp symptomatic and/or large uterine fibroid Current vaginal infection require medication Clinically significant abnormal gynecological finding sign vaginal atrophy ( e.g . uterine vaginal prolapse Grade 2 high ) Previous participation ospemifene study</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Vulvar vaginal atrophy postmenopausal woman</keyword>
	<keyword>Menopausal symptom</keyword>
	<keyword>Vaginal atrophy</keyword>
	<keyword>Urogenital atrophy</keyword>
</DOC>